Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone760-931-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$599.67 million
Profitability
Miscellaneous
Employees737
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its earnings results on Wednesday, August, 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.26. The company had revenue of $164 million for the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. The business's revenue was up 39.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.29) EPS. View Ionis Pharmaceuticals' Earnings History.
When is Ionis Pharmaceuticals' next earnings date?
What price target have analysts set for IONS?
11 equities research analysts have issued 1 year target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $50.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $76.60 in the next year. This suggests a possible upside of 40.0% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.
What is the consensus analysts' recommendation for Ionis Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.
What are Wall Street analysts saying about Ionis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (10/22/2019)
- 2. Cantor Fitzgerald analysts commented, ". $68 PT. Biogen (BIIB, Young, Neutral) reported earnings this morning and discussed the outlook for Spinraza, which is a key product for Ionis (receives low-20s royalty). Incremental color suggests that the broader SMA market, especially ex-US, is likely much larger than initially expected. However, we see disruptive potential from competitors (risdiplam and gene therapy) which continues to leave us cautious on the long-term Spinraza opportunity. We are hosting a conference call on Monday at 10 AM ET to discuss our thoughts on the key SMA competitor updates expected at AAN (early May) and stock reads to IONS, BIIB and PTCT (Overweight, Young). Call details below." (4/24/2019)
Has Ionis Pharmaceuticals been receiving favorable news coverage?
Media stories about IONS stock have trended extremely negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a news sentiment score of -4.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Ionis Pharmaceuticals.
Are investors shorting Ionis Pharmaceuticals?
Ionis Pharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 10,510,000 shares, a decline of 6.7% from the August 30th total of 11,260,000 shares. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is currently 10.1 days. Approximately 8.2% of the company's shares are sold short. View Ionis Pharmaceuticals' Current Options Chain.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
What other stocks do shareholders of Ionis Pharmaceuticals own?
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
- Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
- Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
- Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
- Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)
Who are Ionis Pharmaceuticals' major shareholders?
Ionis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sicart Associates LLC (0.29%), Peregrine Capital Management LLC (0.14%), BLB&B Advisors LLC (0.13%), Decatur Capital Management Inc. (0.05%), Envestnet Asset Management Inc. (0.04%) and Gateway Investment Advisers LLC (0.03%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Which major investors are selling Ionis Pharmaceuticals stock?
IONS stock was sold by a variety of institutional investors in the last quarter, including Decatur Capital Management Inc., Nisa Investment Advisors LLC, Sicart Associates LLC, Envestnet Asset Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , BLB&B Advisors LLC and Stephens Inc. AR. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Which major investors are buying Ionis Pharmaceuticals stock?
IONS stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Robeco Institutional Asset Management B.V., Sumitomo Mitsui DS Asset Management Company Ltd, Coastal Investment Advisors Inc., Gateway Investment Advisers LLC, DNB Asset Management AS and Kistler Tiffany Companies LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.
How do I buy shares of Ionis Pharmaceuticals?
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of IONS stock can currently be purchased for approximately $54.73.
How big of a company is Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a market capitalization of $7.69 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.
What is Ionis Pharmaceuticals' official website?
How can I contact Ionis Pharmaceuticals?
Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
